{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 298,
  "pageCount": 415,
  "prevPage": 297,
  "nextPage": 299,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/298",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-298",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "I have not really talked to colleagues...and one endocrinologist said she did not see a big difference...she just said a lot of her patients didn't respond.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2af-dc371dc7f280",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Background; ~120 PWS patients\nA: “I’m a clinical geneticist and professor of pediatric [redacted]. And I have been taking care of Prader-Willi patients for more than two decades. I initiated several Prader-Willi clinics. Right now, my colleagues take care of the actual clinic patients, and I focus mainly on the research patients. We’re conducting two trials right now. Of course, one of them is ending with Vykat being approved. I’m in an academic institution. I see patients in the clinic, and I do research both clinical and in the lab.”\nQ: “How many patients does your clinic see? I presume your colleagues are consulting with you, and you’re aware of what’s going on.’\nA: “Yeah, I would say close to a hundred at [hospital name redacted], and I would say probably 20 or so patients at [redacted]. They’re mainly adult patients.” – Physician, KOL, and Vykat trial investigator",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1463f05a-2337-47ac-b488-e2bd0f5ded73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "paragraph",
      "text": "Key investigator and author on Vykat paper – little discussion since approval; other endocrinologists not reporting improvement\nQ: “Obviously, people know that you’re an authority on the drug. Was there enthusiasm when the drug was improved? Do you sense a lot of excitement and enthusiasm for people to put their patients on Vykat when you talk to colleagues?”\nA: “I have not really talked to colleagues except for a very few. And one endocrinologist said she did not see a big difference. She just said a lot of her patients didn’t respond….” – Physician, KOL, and Vykat trial investigator",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "605fa927-539a-4476-a2cc-f7cdd9824b7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Only one patient on Vykat despite being one of the largest centers; disinterested to date in pursuing and no discussion yet\nQ: “How many patients do you think you and your colleagues might put on it in the next three to six months? Like, what do you hear from them? Are they excited? Are they cautious and taking a wait-and-see attitude? What are you hearing?”\nA: “I don’t know how difficult it’s going to be…you know, I have not had that discussion with them yet.. I will reach out to them, but I haven’t done that as yet. But thank you for reminding me…” – Physician, KOL, and Vykat trial investigator",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2cc99ff-6e36-4793-82c9-d008431ab9b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“I have not really talked to colleagues...and one endocrinologist said she did not see a big difference...she just said a lot of her patients didn't respond” — Physician, KOL, and Vykat trial investigator",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2af-e2bf039a9665",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae9f7365-5736-464e-87e6-7f6acbc4edaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Trial investigator #2: Key, prominent investigator on multiple Vykat trials and co-author on trial paper; a leading KOL in the field at one of the largest PWS centers in the US, with ~120 patients. One of the largest enrollers. Skeptical of the company with no interest in prescribing Vykat, to the point of exhibiting anger and alarm at the drug. Only aware of one PWS patient still on drug from the trials, despite being one of the largest US centers. The investigator hasn’t even bothered to discuss Vykat with other endocrinologists at the center since FDA approval, given the dismissiveness; and indicated equal disinterest among colleagues: “I have not really talked to colleagues...and one endocrinologist said she did not see a big difference...she just said a lot of her patients didn’t respond”; “you know, I have not had that discussion...I will reach out to them...but thank you for reminding me....”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e848c98c-d1f7-41d6-bce9-c72750e5754f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}